Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity.

ABSTRACT: Although trastuzumab-induced cardiotoxicity is an important determinant to limit the use of this drug, the molecular mechanism of risk for this toxicity is not well understood. To identify genetic variants determining the risk of trastuzumab-induced cardiotoxicity, we carried out whole exome sequencing of germline DNA samples from 9 patients with trastuzumab-induced cardiotoxicity, and conducted a case-control association study of 2258 genetic variants between 9 cases (with trastuzumab-induced cardiotoxicity) and general Japanese population controls registered in the Human Genetic Variation Database (HGVD). The top variant which showed the lowest P-value in the screening study was rs139503277 in PHD Finger Protein 3 (P_min = .00012, odds ratio [OR] = 51.23). To further validate t

SUBMITTER: Udagawa C 

PROVIDER: S-EPMC5797809 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature